Integrating alternative therapies in overcoming chemotherapy resistance in tumors
- 17 February 2025
- journal article
- review article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-15
Abstract
Chemotherapy-resistant tumors present a significant challenge in oncology, often leading to treatment failures owing to mechanisms such as genetic mutations, drug efflux, altered metabolism, and adaptations within the tumor microenvironment. These factors limit the effectiveness of treatment and contribute to tumor resistance. This review highlights the role of alternative therapies aimed at overcoming resistance mechanisms. Several alternative strategies with high efficacy rate against tumor resistance are being explored, including targeted therapies (58–64%), immunotherapy (80%), hormone therapy (22–61%), and emerging approaches such as herbal therapies (90%), probiotics (34–90%), metabolic therapies (> 50%), epigenetic therapies (51–89%), microbiome-based therapies (50%), gene therapy (67–80%), photodynamic therapy/hypothermia (86–99%), and nanotechnology (50–67%). Integrating these alternative strategies with conventional treatments has the potent-al to augment the therapeutic efficacy and patient outcomes. Despite this progress, limitations in cancer therapeutics include the lack of predictive biomarkers, resistance mechanisms, and tumor heterogeneity, all of which contribute to treatment failure and relapse. To address these limitations, advancements in molecular diagnostics, as well as early detection through liquid biopsies, and the use of biomarkers to monitor resistance and guide treatment are crucial. Additionally, expanding clinical trials is essential to validate new therapies and improve patient outcomes.Keywords
This publication has 101 references indexed in Scilit:
- Role of tumor microenvironment in cancer progression and therapeutic strategyCancer Medicine, 2023
- Technological advancements in cancer diagnostics: Improvements and limitationsCancer Reports, 2023
- Immunotherapy: an alternative promising therapeutic approach against cancersMolecular Biology Reports, 2022
- Role of Biomarkers in Prediction of Cardiotoxicity During Cancer TreatmentCurrent Treatment Options in Cardiovascular Medicine, 2018
- Paraptosis‐Inducing Nanomedicine Overcomes Cancer Drug Resistance for a Potent Cancer TherapySmall, 2018
- Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical ExperienceAdvances in Therapy, 2017
- Targeted therapy in cancerCancer Chemotherapy and Pharmacology, 2015
- Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98Breast Cancer Research and Treatment, 2007
- Endocrine therapy – current benefits and limitationsBreast Cancer Research and Treatment, 2005
- Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymphnodes in stage IV head and neck patientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1994